|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 December 2003, Vol. 102, No. 13, pp. 4312-4319. Prepublished online as a Blood First Edition Paper on August 21, 2003; DOI 10.1182/blood-2003-04-1251.
GENE THERAPY
Correction of a mouse model of sickle cell disease: lentiviral/antisickling
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and methodsResultsDiscussionReferences |
|---|
-globin gene. These cells, which were transduced in the absence of cytokine stimulation, fully reconstitute irradiated recipients and correct the hemolytic anemia and organ pathology that characterize the disease in humans. The mean increase of hemoglobin concentration was 46 g/L (4.6 g/dL) and the average lentiviral copy number was 2.2; therefore, a 21-g/L /vector copy increase (2.1-g/dL) was achieved. This transduction protocol may be directly translatable to patients with sickle cell disease who cannot tolerate current bone marrow mobilization procedures and may not safely be exposed to large viral loads. (Blood. 2003;102:4312-4319) |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
-globin gene.1,2 This mutation results in the substitution of a valine residue for glutamic acid on the surface of hemoglobin S (HbS; 
22S) tetramers. The valine creates a hydrophobic projection that fits into a natural hydrophobic pocket formed on hemoglobin tetramers after deoxygenation.3,4 The interaction of tetramers results in the formation of HbS polymers/fibers that cause red blood cells (RBCs) to become rigid and nondeformable and to occlude small capillaries.5-10 These vaso-occlusive events cause severe tissue damage that can result in strokes, splenic infarction, kidney failure, liver and lung disorders, painful crises, and other complications.11,12 Cycles of erythrocyte sickling also cause the cells to become fragile, and lysis produces chronic anemia. Although sickle cell anemia was the first hereditary disease to be understood at the molecular level,1,2 there is still no adequate long-term treatment or cure. Current measures focus on induction of fetal hemoglobin to inhibit polymer formation, treatment and prevention of infections, palliative measures to control pain, and surgical treatment of complications.12 Allogeneic bone marrow transplantation is the only available cure, but this procedure is limited to a minority of patients with an available, histocompatible donor.13
Autologous transplantation of bone marrow stem cells that are transduced with a stably expressed, antisickling globin gene would benefit a majority of patients with SCD. Recently, several groups have used lentiviral vectors for globin gene transfer to bone marrow mononuclear cells and this work has resulted in the correction of sickle cell anemia and -thalassemia in relevant mouse models of these human diseases.14-17 Although these studies represent major advances in gene therapy for hemoglobinopathies, the transduction protocols that were used cannot be directly translated to human patients. In all of the cases referenced above, donor bone marrow cells were mobilized by treating the mice with 5-fluorouracil (5-FU). The equivalent treatment in humans is mobilization of hematopoietic stem cells (HSCs) with granulocyte colony-stimulating factor (G-CSF) or stem cell factor (SCF) or both. This treatment is effective for mobilizing bone marrow HSCs into peripheral blood and these HSCs successfully engraft in recipients.13 Unfortunately, G-CSF cannot be used safely in patients with SCD. Abboud et al18 have described severe sickle cell crisis in a patient receiving G-CSF, and Adler et al19 reported the death of a patient with SCD whose bone marrow was mobilized with G-CSF. This latter patient was 47 years old and had no previous history of sickle cell crisis. SCF, which has also been used to mobilize bone marrow, is associated with anaphylaxis and other serious adverse effects that preclude its use in a transplantation protocol for sickle cell patients.20
Another difficulty with the transduction protocol used in recent gene therapy studies for hemoglobinopathies is the ex vivo stimulation of HSCs with cytokines. This treatment is included in the protocols to increase the number of stem cells that are actively progressing through the cell cycle and, therefore, to increase the efficiency of retroviral or lentiviral transduction. Unfortunately, cytokine stimulation of HSCs and premature exit from quiescence can decrease self-renewing capacity, homing efficiency, and, therefore, long-term engraftment in mice and in humans.21-25 Although retroviral transduction requires cell division,26,27 efficient lentiviral transduction can occur in quiescent cells.28-31 We recently demonstrated that unmobilized HSCs derived from murine bone marrow are efficiently transduced with a lentiviral vector in the absence of cytokine stimulation and that the transduced gene is expressed in all hematopoietic cell lineages examined for at least 5 months after transplantation into lethally irradiated recipients.32 These results suggest that quiescent, unmobilized HSCs are efficiently transduced by lentiviral vectors without impairing self-renewal and normal lineage specification in vivo. Therefore, the protocol that we have adopted for our globin gene transfer studies does not include cytokine stimulation.
A final problem with the lentiviral transduction protocols used previously is the large amount of virus used. Several million bone marrow mononuclear cells are transduced at a multiplicity of infection (MOI) of 60 or more and transplanted into recipients; therefore, each animal is exposed to more than 1 x 108 lentiviral particles.15,16 Replication-defective lentiviral vectors appear to be safe in animal models; however, clinical trials in humans will most likely be approved only for protocols using minimal amounts of virus. Therefore, we have developed a protocol that exposes the animals to at least 3000 times less lentiviral vector than previous protocols by transducing highly purified HSCs (Sca-1+, c-Kit+, Lin-/low) at an MOI of approximately 30.
|
Materials and methods |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
A 2.3-kb recombinant human AS3 gene (T.M.R. et al, unpublished, May 1995) and 3.4 kb of human -globin locus control region (LCR) sequences were subcloned into pWPT-GFP (a kind gift from Dr Didier Trono) replacing the EF1 promoter and green fluorescent protein (GFP). This self-inactivating (SIN) vector contains a deletion in the U3 region of the 3' long terminal repeat (LTR) from nucleotide 418 to nucleotide 18 that inhibits all transcription from the LTR.33 The AS3-globin gene contains 266 bp of promoter, the 260-bp PstI 3' globin enhancer,34 and a 375-bp RsaI fragment deletion of IVS2.35 DNase I hypersensitive site (HS) fragments, 5' HS4, 3, and 2 were amplified by polymerase chain reaction (PCR) from a 22-kb fragment of the LCR.36,37 Nucleotide coordinates from GenBank accession no. U01317
[GenBank]
are: HS4 592-1545, HS3 3939-5151, and HS2 8013-9215. The entire HS4, 3, 2 AS3-globin gene construct was verified by sequencing. Vectors were produced by transient transfection into 293T cells as previously described38 with the following modifications. A total of 2.5 x 106 293T cells were seeded in 10-cm-diameter dishes containing Dulbecco modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS) 24 hours prior to transfection. Forty micrograms plasmid DNA was used for transfection of one 10-cm dish. The DNA cocktail contained 5 µg envelope-coding plasmid pMD.G, 15 µg of the packaging plasmid pCMVDR8.91 (which expresses Gag, Pol, Tat, and Rev) and 20 µg SIN transfer vector plasmid. Transfection medium was removed after 14 to 16 hours and replaced with DMEM/F12 without phenol red (Invitrogen, Carlsbad, CA) containing 2% FBS. Viral containing supernatant was collected after an additional 24 hours, cleared by low-speed centrifugation, and filtered through a low protein-binding 0.22-µm polyethersulfone filter (Millipore, Beford, MA). The virus was concentrated 1000-fold by one round of centrifugation at 26 000 rpm for 90 minutes at 8°C using an SW-28 rotor (Beckman, Palo Alto, CA), resuspended into serum-free stem cell growth medium (SCGM) (Cellgenix, Freiburg, Germany) and allowed to incubate on ice for 2 hours before storage at -80°C. Virus titer was determined by infecting murine erythroleukemia (MEL) cells, plating individual cells into wells of a 96-well plate, and assaying DNA from the cultures by PCR for the human AS3-globin gene.
Murine bone marrow cell preparation and stem cell sorting
HSCs from our SCD mice39 were obtained as previously described with minor modifications.32 Briefly, bone marrow cells were flushed from the femurs and tibias of SCD mice and stained with a biotinylated Sca-1 antibody (clone E13-161.7; BD-Biosciences, San Diego, CA) followed by an antibiotin magnetic bead (Miltenyi Biotec, Auburn, CA) and fluorescein isothiocyanate (FITC)-conjugated streptavidin (Caltag, Burlingame, CA). Sca-1 cells were then isolated on a magnetic-activated cell sorter (MACS; Miltenyi Biotec). The Sca-1-enriched cells were then stained with phycoerythrin (PE)-conjugated antibodies directed against lineage antibodies CD3, 145-2C11; CD4, RM4-5; CD5, 53-7.3; CD8, 53-6.7; CD11b (Mac-1), M1/70; Gr-1, RB6-8C5; CD45RA, RA3-6B2; and TER119/Ly-76, TER119 (BD-Biosciences) followed by staining with allophycocyanin (APC)-conjugated c-Kit (clone 2B8; BD-Biosciences). Cells were washed once and resuspended in Iscove modified Dulbecco medium (IMDM) containing 2% FBS for fluorescence-activated cell sorting (FACS) on a FACSVantage SE (BD-Biosciences) flow cytometer. Sca-1+c-Kit+Lin-/low cells were collected into IMDM containing 1% FBS for transduction.
Purification of bone marrow Ter119+ and CD11b(Mac-1)+ and Gr1+ cells from secondary transplants was accomplished by staining bone marrow mononuclear cells with PE-conjugated antibodies directed against Ter119 or against CD11b(Mac-1) and Gr1 and sorting on a FACSVantage SE (BD-Biosciences) flow cytometer. DNA was obtained from approximately 1 x 105 purified cells using the Qiagen (Valencia, CA) DNeasy kit.
Congenic knockout-transgenic sickle mice and HSC preparation
Congenic knockout-transgenic (KO-TG) SCD mice were generated from line HbS539 by backcrossing mouse -globin knockout,40 mouse -globin knockout,41 and LCR/LCRA
s transgenic39 mice to the C57Bl/6 (B6) strain in parallel. After 8 successive backcross generations these 3 B6 congenic lines were interbred to generate KO-TG-B6 SCD mice that synthesize solely human hemoglobin in their adult RBCs. These backcrosses were performed to inhibit graft-versus-host reactions in long-term reconstituted recipients. The animals are extremely anemic on the C57Bl/6 background; hemoglobin levels are as low as 23 g/L (2.3 g/dL). Both the HbS5 and HbS3 lines that we originally reported39 were backcrossed onto C57Bl/6. The HbS3 line, which has balanced - and -globin chains, was so severely anemic on the C57Bl/6 background that the line could not be used for these experiments. The HbS5 line is slightly -thalassemic, similar to the BERK mice,42 and survives longer on the C57Bl6/background. Therefore, we used this line for these studies.
Stem cell transduction and transplantation
Sorted Sca-1+, c-Kit+, Lin-/low stem cells were resuspended in IMDM medium containing 10 µg/mL dextran sulfate and 1% FBS. One thousand stem cells were infected at an MOI of 30 in a total volume of 100 µL at 37°C in 5% CO2 for 4 hours. Mock- or lenti AS3-transduced stem cells were injected into the retro-orbital sinus of anesthetized 8-week-old C57Bl/6 mice that were lethally irradiated (1325 cGy administered in a split dose). Hematopoietic reconstitution with donor HSCs from the sickle mice was monitored by analyzing the replacement of murine hemoglobin polypeptides with human hemoglobin polypeptides using high-performance liquid chromatography (HPLC) as described previously.39 Secondary transplantations were performed with one million unfractionated mononuclear cells isolated from primary transplants. The cells were injected into lethally irradiated C57Bl/6 mice and hemoglobin levels were analyzed 4 months after transplantation.
Lenti/AS3 vector copy number determination
The lenti/AS3 vector copy number in transplanted mice was determined by an allele-specific assay. Transplant bone marrow DNA was obtained using the Qiagen DNeasy kit. Bone marrow DNA was amplified by PCR with primers that anneal to identical sequences in the human S- and AS3-globin genes. These primers do not amplify mouse -globin. The sequences of the forward and reverse primers are 5'-ACATTTGCTTCTGACACAACT-3' and 5'-GGGAAAATAGACCAATAGGC-3', respectively. Twenty-five cycles of PCR were performed with unlabeled primers followed by one cycle of primer extension with 5' [32P]-labeled reverse primer. Twenty-five cycles of PCR were within the linear range of amplification. The resulting 264-bp amplicon was digested with Bsu36I that cuts only the AS3-globin gene, producing a 194-bp restriction fragment. After complete digestion, the resulting radiolabeled fragments were separated on a 2% Tris-borate-EDTA (TBE; tris(hydroxymethyl)aminomethane; ethylenediaminetetraacetic acid) agarose gel. The copy number of the human S allele was determined by the same method as for lenti/AS3 except that S-globin was compared to mouse -globin in sickle animals that were heterozygous for the mouse -globin knockout. Forward and reverse primers complementary to identical sequences in the mouse and human -globin genes were 5'-ATGAAGTTGGTGGTGAGC-3' and 5'-AGACTCACCCTGAAGTTCTC-3', respectively. Twenty-seven cycles of PCR were performed with unlabeled primers followed by one cycle of primer extension with 5' [32P]-labeled forward primer. Twenty-seven cycles of PCR were within the linear range of amplification. The resulting 389-bp amplicon was digested with SacI that cuts only the mouse -globin gene, producing a 337-bp restriction fragment. Using this allele-specific PCR methodology to analyze transgene (LCRAs) copy number, we determined that the mice contain 3 copies of the human S gene. DNA bands were quantified with a Molecular Dynamics Storm Phosphorimager (Amersham Biosciences, Piscataway, NJ) and the ratio of lenti/AS3 to LCRAs was determined by IMAGE-QUANT software (Amersham Biosciences).
Globin protein analysis
Although the AS3 polypeptide differs from S by 4 amino acids, we were unable to discriminate the 2 species using HPLC. Therefore, hemoglobins were separated by isoelectric focusing (IEF) of hemolysates as described previously.43,44 Briefly, IEF was performed using the isothermal controlled electrophoresis system (Fisher Scientific, Pittsburgh, PA) with precast agarose IEF gels (Isolab, Akron, OH). Hemoglobin bands were quantitated by densitometry with a Bio-Rad (Hercules, CA) GS-800 scanner using Quantity One software. HbS and HbAS3 bands focused at the same isoelectric point as HbS and HbAS3 purified from transgenic/knockout mice that synthesize these hemoglobins exclusively. HbAS3 bands were also confirmed by tryptic digestion and analysis by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.
Single-cell expression level analysis
Analysis of mRNA levels was performed on peripheral blood reticulocytes isolated from animals receiving transplants with the lenti-AS3 vector. Reticulocytes were stained with thiazole orange,45 purified on a FACScan flow cytometer (BD-Biosciences) and plated after limit dilution at one cell per 3 wells in a 96-well plate. Plates were stored at -80°C for 1 hour and cells were thawed into 2.5 µL lysis buffer (1.6% IGEPAL/NP-40; Sigma, St Louis, MO). Reverse transcription (RT) was performed with Superscript II RT (Invitrogen) according to manufacturer's recommendations. Two microliters of the RT reaction were used to perform PCR with ExTaq (Panvera-TaKaRa, Madison, WI). As described for gDNA PCR, the primers used for RT-PCR anneal to sequences that are identical in the human S and human AS3 globin genes. The forward primer sequence was 5'-ACATTTGCTTCTGACACAACT-3' (5' untranslated region) and the reverse primer was 5'-CCATAACAGCATCAGGAGTG-3' (2nd exon). Thirty-five cycles of PCR were performed with unlabeled primers and then one cycle of primer extension was performed with 5' -[32P]-labeled reverse primer. This cycle number was within the linear range of amplification. The resulting 222-bp PCR product was digested with Bsu36I that cuts AS3 and yields a 151-bp fragment. After complete digestion, the resulting radiolabeled fragments were separated on an 8% acrylamide gel.
Hematologic indices and histopathology
Blood was collected from anesthetized animals into Microtainer EDTA collection tubes. RBC count was measured on a HemaVet 1500 hematology analyzer (CDC Technology, Oxford, CT). Hemoglobin concentration was determined spectrophotometrically after conversion to cyanmethemoglobin with Drabkin reagent (Sigma). Before determining the hemoglobin concentration, RBC membranes were pelleted at 14 000 rpm for 5 minutes in an Eppendorf centrifuge. Pelleting the membranes inhibits artifactually high values caused by membrane-bound, denatured hemoglobin. Packed cell volume (PCV) was measured with a JorVet J503 (Jorgenson Laboratories Systems, Loveland, CO) microhematocrit centrifuge. Reticulocyte count was determined by flow cytometry after staining with thiazole orange. Urine osmolality was measured with the Wescor Vapro Vapor Pressure Osmometer 5520 (Wescor, Logan, UT) after food and water were withheld from the mice for 4 hours. Tissues were fixed in 70% alcoholic formalin, embedded in paraffin, sectioned, and stained with hematoxylin-eosin or Gomori iron stain by standard methods.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
We previously demonstrated that substitution of an alanine at position 22 and glutamine at position 87 of the human -globin polypeptide (AS2) significantly inhibits HbS polymerization.46 We have now introduced an additional modification that increases the affinity of -globin subunits for -globin polypeptides and results in a molecule that impedes polymer formation with greater efficiency than fetal hemoglobin (HbF; T.M.R. et al, unpublished data). This antisickling gene, AS3-globin, was inserted into an SIN lentiviral vector33 to form the construct designated lenti/AS3 (Figure 1B). The selection of -globin promoter, enhancer, and LCR elements was based on our previous studies analyzing the expression of human -globin genes in transgenic mice.34,36,47,48 Lenti/AS3 contains the central polypurine tract/DNA flap for increased packaging efficiency, viral titer, and transduction efficiency49,50 and the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) that increases the efficiency of RNA processing and contributes to the production of full-length viral transcripts.51 Lenti/AS3 was pseudotyped with the vesicular stomatitis virus G (VSV-G) glycoprotein and concentrated to a final titer of 1 x 108 infectious units/mL as described in "Materials and methods."
|
Transduction and transplantation of Sca-1+c-Kit+Lin- SCD HSCs
As described (see "Introduction"), mobilization of bone marrow stem cells with cytokines such as G-CSF and SCF cannot be safely performed in sickle cell patients. Therefore, we used a transduction protocol that does not include mobilization.32 Bone marrow was isolated from untreated KO-TG-B6 SCD (sickle) mice, and HSCs that were positive for stem cell antigen (Sca-1+) and c-Kit+, and negative (or low) for hematopoietic lineage antigens (lin-/low) were isolated by preparative flow cytometry (Figure 2).52,53 Without cytokine prestimulation, 1000 Sca-1+, c-Kit+, lin-/low (KLS) stem cells were transduced for 4 hours with lenti/AS3 at an MOI of 30. This relatively low amount of virus was used to minimize exposure of the animals to lentivirus and to reduce the possibility of insertional mutagenesis. Transduced HSCs were transplanted into lethally irradiated (1325 cGy), wild-type C57Bl/6 recipients and reconstitution was quantified by HPLC analysis of hemoglobins (Figure S1; see the Supplemental Figure link at the top of the online article on the Blood website). Animals that expressed more than 99% human hemoglobin 12 weeks after transplantation were identified and retained for long-term analysis. This high level of donor cell engraftment precludes artifactual amelioration of anemia resulting from the presence of residual murine RBCs.
|
Vector copy number was determined by allele-specific PCR of bone marrow DNA. Lenti/AS3 was present at 2.2 ± 0.3 (SE) proviral units per transduced cell (Figure 1C).
Therapeutic expression levels of human AS3in murine erythrocytes following lentiviral gene transfer into purified HSCs
At 5 to 7 months after transplantation, peripheral blood was collected from lenti/AS3 and mock-transduced animals. Hemolysates were prepared and hemoglobins (HbS and HbAS3) were separated by IEF. All of the fully reconstituted animals expressed 20% to 25% HbAS3 and 75% to 80% HbS (Figure 3A). Bone marrow was isolated from several of these animals and transplanted into lethally irradiated secondary recipients. The last lane of Figure 3A (TP20) is a hemolysate from a representative secondary recipient 7 months after transplantation; HbAS3 is 20% of total hemoglobin. These results demonstrate that unmobilized, unstimulated HSCs are stably transduced for up to 14 months with lenti/AS3.
|
The fraction of erythroid cells that express AS3 was determined by single-cell, allele-specific RT-PCR. Reticulocytes were isolated by FACS and individual cells were analyzed for AS3 and S mRNA. The primers for AS3 and S amplification were identical, and PCR products were distinguished by digestion with Bsu36I, which cuts AS3 but not S amplicons. Figure 3B illustrates the results for several individual reticulocytes and for a population of cells from a representative lenti/AS3 mouse. Eighty-five percent (17 of 20) of the reticulocytes that were examined contained AS3 mRNA. Individual reticulocyte levels of human AS3-globin mRNA ranged from a low of 10% to a high of 43% of human S-globin mRNA. The level of AS3-globin mRNA expression in the entire population was 24%, and this level is consistent with the level of HbAS3 detected in the IEF gel.
All secondary recipients expressed between 20% and 25% HbAS3 7 months after transplantation (see representative sample in Figure 3A). Figure 3C demonstrates that FACS-purified bone marrow granulocytes/macrophages (G/M; Gr1+/Mac1+), erythroid progenitors (T;Ter119+), and whole bone marrow (WBM) from 3 of these secondary recipients (7 months after transplantation) contain an average lenti/AS3 copy number of 1.9. Similar vector copy numbers for G/Ms, erythroid progenitors, and WBM in individual recipients suggest that HSCs are transduced and that corrected erythroid progenitors are not selectively amplified in the marrow.
Correction of abnormal RBC morphology and hematologic parameters in Lenti/AS3-corrected SCD mice
Figure 4 illustrates blood smears from animals given transplants with mock-transduced and lenti/AS3-transduced sickle HSCs 5 months after transplantation. Many rigid, elongated cells are observed in the mock-transduced control (Figure 4A); however, no sickled cells are observed in lenti/AS3 mice (Figure 4C-D showing 2 representative animals). Figure 4B shows a wild-type control. The blood smears of lenti/AS3 animals also lack the anisocytosis, poikilocytosis, and polychromasia characteristic of the erythrocyte morphology observed in SCD mice and HbSS patients.11,39 Table 1 compares hematologic indices of control, sickle, mock-transduced, and lenti/AS3-transduced mice. Lenti/AS3 animals have a marked increase in RBC counts, hemoglobin levels, and hematocrit values, and a significantly reduced reticulocytosis compared with mock-transduced controls. The 46 g/L (4.6 g/dL) rise in hemogloblin level (27 to 73 g/L [2.7 to 7.3 g/dL]) was achieved with a lenti/AS3 copy number of 2.2 proviral units per cell. This increase of 21 g/L/proviral copy (2.1 g/dL) compares favorably with the values reported for correction of another sickle mouse model by Pawliuk et al (19 g/L/copy [1.9 g/dL/copy])15 and for correction of a -thalassemia mouse model by May et al (38 g/L/copy [3.8 g/dL/copy]),14 Rivella et al (23 g/L/copy [2.3 g/dL/copy]),54 Imren et al (15 g/L/copy [1.5 g/dL/copy]),16 and Persons et al (11 g/L/copy [1.1 g/dL/copy]).17 The last line of Table 1 demonstrates that secondary recipients at 7 months after transplantation retain the marked increases in RBC counts, hemogloblin concentrations, and hematocrit levels and reduced reticulocytosis compared with mock-transduced controls.
|
|
Sickled erythrocytes are not observed in blood smears or in tissues of lenti/AS3 mice; however, the animals remain significantly anemic with hemoglobin concentrations of 73 g/L (7.3 g/dL). This persistent anemia despite a 46-g/L (4.6-g/dL) rise in hemoglobin level is a consequence of the extremely low baseline hemoglobin concentrations in sickle animals that are bred onto the C57B/6 background (27 g/L [2.7 g/dL]). We do not know the reasons for this strain-dependent, severe anemia but we are currently examining genes that modify disease severity. A 46-g/L (4.6-g/dL) increase in hemoglobin in human sickle patients would dramatically reduce anemia.
Amelioration of spleen, liver, and kidney pathology; restoration of kidney function in sickle mice
Recipients of lenti/AS3-transduced sickle HSCs developed little spleen, liver, and kidney pathology compared with recipients of mock-transduced cells. Histologic sections of wild-type, mock-transduced, and lenti/AS3 animals are shown in Figure 5A. The spleens of mock-transduced mice are characterized by a massive expansion of red pulp, dramatic pooling of sinusoidal erythrocytes, vaso-occlusion, and a complete loss of lymphoid follicular structure. In lenti/AS3-transduced mice, normal splenic red and white pulp is observed and virtually no pools of sickle erythrocytes or infarcts are evident. In addition, splenomegaly is substantially diminished in lenti/AS3 mice (Figure 5B); lenti/AS3 spleens are approximately 0.7% of total body weight compared with mock-transduced spleens that are almost 2.0% of body weight.
|
Livers of mock-transduced animals are characterized by focal areas of necrosis and pronounced congestion of the intrahepatic vasculature with aggregates of sickled RBCs. Erythroid progenitors are evident in the sinusoids and this extramedullary hematopoiesis is indicative of severe anemia. There is also abundant hemosiderin deposition subsequent to Kupffer cell erythrophagocytosis. In lenti/AS3 animals, focal areas of necrosis and aggregation of sickled erythrocytes are not observed; also, extramedullary hematopoiesis and hemosiderin deposition are absent.
In the kidneys of mock-transduced mice, engorgement and occlusion of blood vessels result in vascular, tubular, and glomerular changes. Sequestration and occlusion are most obvious at the corticomedullary junction where dilated capillaries are easily observed in this region of reduced oxygen tension. Reduced medullary blood flow in HbSS patients causes extensive tubular damage that results in hyposthenuria, and this same loss of ability to concentrate urine is observed in the sickle mice. Kidneys of mock-transduced animals also accumulate abundant hemosiderin in the cortical region and these aggregates are easily visualized with Gomori iron staining (Figure 5A, bottom panels). In contrast, kidneys of lenti/AS3 mice appear normal and free of the disruptive vascular RBC pooling and hemosiderin deposits observed in mock-treated animals. Most importantly, urine-concentrating ability is almost completely restored in lenti/AS3 mice and this restoration is maintained in secondary recipients at 7 months after transplantation (Table 1).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
-globin gene into purified HSCs. The correction was accomplished with a transduction protocol that should be translatable to human patients. The protocol does not include mobilization of bone marrow or cytokine stimulation of HSCs. Bone marrow mobilization protocols are not safe for sickle cell patients because rapid increases in leukopoiesis are associated with vascular crises that can result in death.18,19 Therefore, we collected bone marrow from animals in the absence of pretreatment with 5-FU or G-CSF. We also used quiescent HSCs that were not stimulated with cytokines prior to or during transduction. Most, if not all, cytokine pretreatment protocols induce some measure of HSC differentiation and loss of long-term repopulating activity21-25; therefore, autologous and allogenic bone marrow transplantation protocols in humans typically do not use cytokine pretreatments.13 Our previous results with a lenti/CMV-GFP vector demonstrated that efficient lentiviral transduction of purified HSCs does not require cytokine induction of cell cycle progression32; therefore, we used the same protocol in the lenti/AS3 studies described in this paper.
At 5 to 7 months after transplantation, we analyzed lenti/AS3 mice that were reconstituted with more than 99% donor cells, and all of these animals were corrected; all mock-transduced controls developed severe disease. Secondary lenti/AS3 transplants were also corrected for at least 7 months after transplantation. These results demonstrate that long-term repopulating cells are stably transduced. Interestingly, 75% to 85% of reticulocytes in these animals synthesized AS3 mRNA. This nearly pancellular expression was unexpected using a nonmobilizing transduction protocol in the absence of cytokine prestimulation. These results suggest that transduction of relatively quiescent HSCs was efficient with our protocol.
Hematologic values of mice given transplants with lenti/AS3-transduced HSCs were dramatically improved. RBC counts, hematocrit values, and hemoglobin levels were markedly increased and reticulocyte numbers were reduced from 69% to 14%. Although some anemia was still evident in these animals, the mice mimicked sickle patients with hereditary persistence of fetal hemoglobin (HPFH). HPFH patients who synthesize 20% HbF typically have mild disease and lead relatively normal lives.
Tissue pathology was almost completely corrected in the lenti/AS3-transduced animals. No splenic infarction, liver necrosis, or kidney corticomedullary damage was observed, and urine-concentrating ability was restored to normal levels. These results demonstrate that a single dose of lenti/AS3 can correct SCD and that this correction is stable for the lifetime of the animal and in secondary transplant recipients.
Concerns about viral transduction of hematopoietic cells have recently been raised by the development of leukemia in 2 patients with severe combined immunodeficiency (SCID) who were treated by gene therapy.55,56 Insertion of the retroviral vector near the LMO-2 gene apparently stimulated expression of this proto-oncogene that normally regulates crucial steps in hematopoiesis.57 Activation of oncogenes by enhancer sequences present in the LTRs of retroviruses has been reported in the literature58 and these LTR enhancers can activate genes at distances approaching 100 kb.59 Although insertional activation of proto-oncogenes by lentiviral LTR enhancers has not been reported, we used a SIN lentiviral vector in our studies to minimize these events.
We also attempted to minimize insertional activation/mutagenesis by limiting the total amount of virus in our transduction protocol. Low levels of viral exposure were possible because highly purified HSCs were transduced instead of whole bone marrow or partially purified cells. At least 3000 times less lentivirus was used compared with previous protocols by transducing and transplanting only 1000 Sca-1+, c-Kit+, Lin-/low cells. This procedure limits vector integration into committed progenitors and mature cells that are abundant in total mononuclear cell preparations. Mature donor T and B cells can persist for long periods of time in transplant recipients. These cells replicate actively and are responsible for the acquisition of donor immunity in allogeneic recipients.60-62 Vector insertions in these cells and in other committed lineages, which can be transformed,63,64 may increase the risk of insertional activation of proto-oncogenes such as LMO-2. We did not observe leukemias in any of our primary or secondary transplant recipients.
Finally, the use of low levels of virus in our transduction protocol may also minimize the probability of generating replication competent lentivirus. Although the probability of recombination between the lentiviral vector and endogenous viral-like sequences is low, a 3000-fold decrease in viral exposure should reduce the frequency of recombination even further.
In summary, we have corrected SCD disease in a mouse model that mimics most if not all of the pathology of this severe disease. Our transduction protocol, which uses highly purified, unmobilized HSCs and minimal exposure to the self-inactivating lenti/AS3 vector, may be effectively and safely translated to human patients.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by National Institutes of Health (NIH) Predoctoral Fellowship Training Grant 5 T32 CA09467 (D.N.L.) and NIH Grant HL57619 (T.M.T.).
Prepublished online as Blood First Edition Paper, August 21, 2003; DOI 10.1182/blood-2003-04-1251.
The online version of the article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Tim M. Townes, 502 Kaul Genetics Bldg, 720 20th St S, Birmingham, AL 35294; e-mail: ttownes{at}uab.edu.
|
References |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
-thalassaemia created by gene targeting in mice and its genetic rescue. Nat Genet. 1995;11: 11-39.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Related Article in Blood Online:
This article has been cited by other articles:
|
|
 |
|
  H. Zhao, T. I. Pestina, M. Nasimuzzaman, P. Mehta, P. W. Hargrove, and D. A. Persons Amelioration of murine {beta}-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both {gamma}-globin and the MGMT drug-resistance gene Blood, June 4, 2009; 113(23): 5747 - 5756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-W. Chang, Y.-S. Lai, K. M. Pawlik, K. Liu, C.-W. Sun, C. Li, T. R. Schoeb, and T. M. Townes Polycistronic Lentiviral Vector for "Hit and Run" Reprogramming of Adult Skin Fibroblasts to Induced Pluripotent Stem Cells Stem Cells, May 1, 2009; 27(5): 1042 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. R. Su, J. L. Blakemore, Y. Zhang, M. F. Linton, and S. Fazio Lentiviral Transduction of ApoAI Into Hematopoietic Progenitor Cells and Macrophages: Applications to Cell Therapy of Atherosclerosis Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1439 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Moi and M. Sadelain Towards the genetic treatment of {beta}-thalassemia: new disease models, new vectors, new cells Haematologica, March 1, 2008; 93(3): 325 - 330. [Full Text] [PDF]
|
|
|
|
|
|
L. Lisowski and M. Sadelain Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in -thalassemic mice Blood, December 15, 2007; 110(13): 4175 - 4178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Cheng, K. M. Sakamoto, E. M. Horwitz, S. L. Karsten, L. Shoemaker, H. I. Kornblumc, and P. Malik Report on the Workshop "New Technologies in Stem Cell Research," Society for Pediatric Research, San Francisco, California, April 29, 2006 Stem Cells, April 1, 2007; 25(4): 1070 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Pan, J. M. Scarlett, T. T. Luoh, and P. Kurre Prolonged Adherence of Human Immunodeficiency Virus-Derived Vector Particles to Hematopoietic Target Cells Leads to Secondary Transduction In Vitro and In Vivo J. Virol., January 15, 2007; 81(2): 639 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-C. Wu, C.-W. Sun, T. M. Ryan, K. M. Pawlik, J. Ren, and T. M. Townes Correction of sickle cell disease by homologous recombination in embryonic stem cells Blood, August 15, 2006; 108(4): 1183 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bot, J. Guo, M. Van Eck, P. J. Van Santbrink, P. H. E. Groot, R. B. Hildebrand, J. Seppen, T. J. C. Van Berkel, and E. A. L. Biessen Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo Blood, August 15, 2005; 106(4): 1147 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Walters Stem Cell Therapy for Sickle Cell Disease: Transplantation and Gene Therapy Hematology, January 1, 2005; 2005(1): 66 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Puthenveetil, J. Scholes, D. Carbonell, N. Qureshi, P. Xia, L. Zeng, S. Li, Y. Yu, A. L Hiti, J.-K. Yee, et al. Successful correction of the human {beta}-thalassemia major phenotype using a lentiviral vector Blood, December 1, 2004; 104(12): 3445 - 3453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Hematti, S. Tuchman, A. Larochelle, M. E. Metzger, R. E. Donahue, and J. F. Tisdale Comparison of Retroviral Transduction Efficiency in CD34+ Cells Derived from Bone Marrow versus G-CSF-Mobilized or G-CSF Plus Stem Cell Factor-Mobilized Peripheral Blood in Nonhuman Primates Stem Cells, November 1, 2004; 22(6): 1062 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hanawa, P. W. Hargrove, S. Kepes, D. K. Srivastava, A. W. Nienhuis, and D. A. Persons Extended {beta}-globin locus control region elements promote consistent therapeutic expression of a {gamma}-globin lentiviral vector in murine {beta}-thalassemia Blood, October 15, 2004; 104(8): 2281 - 2290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Levasseur, T. M. Ryan, M. P. Reilly, S. L. McCune, T. Asakura, and T. M. Townes A Recombinant Human Hemoglobin with Anti-sickling Properties Greater than Fetal Hemoglobin J. Biol. Chem., June 25, 2004; 279(26): 27518 - 27524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hanawa, P. Hematti, K. Keyvanfar, M. E. Metzger, A. Krouse, R. E. Donahue, S. Kepes, J. Gray, C. E. Dunbar, D. A. Persons, et al. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system Blood, June 1, 2004; 103(11): 4062 - 4069. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
-globin gene transduction of unmobilized, purified hematopoietic stem cells
indicates packaging signal; SD and SA, splice donor and acceptor sites, respectively; RRE, Rev-responsive element; cPPT/CTS, central polypurine tract or DNA flap/central termination sequence; and WPRE, woodchuck hepatitis virus post-transcriptional regulatory element. (C) Lentiviral vector copy number determination. Lane 1 is the PCR product obtained from bone marrow of a KO-TG sickle mouse after amplification, labeled primer extension, and Bsu36I digestion; lanes 2, 3, and 4 are products of representative lenti/
